The US Food and Drug Administration will likely continue to use remote inspection alternatives that emerged during the COVID-19 pandemic in a “hybrid approach” with in-person inspections, not in place of them, says assistant commissioner Elizabeth Miller.
Speaking at the Association for Accessible Medicines’s Generics + Biosimilars conference on 9 November, Miller said that FDA does not intend to replace traditional good